A study by scientists at Scripps Research and UC San Diego has identified erucamide as a naturally occurring molecule that may help protect the retina from degeneration, pointing towards new therapeutic strategies for progressive vision loss diseases.
In a significant advancement for understanding retinal diseases, researchers at Scripps Research, in collaboration with scientists from UC San Diego and the Lowy Medical Research Institute, have identified a naturally occurring molecule known as erucamide that appears to play a crucial role in the retina’s response to injury. The study, published in the journal Nature Neuroscience on June 19, 2026, sheds light on the chemical signals that could potentially help slow down diseases that lead to progressive vision loss.
The retina is the light-sensitive tissue located at the back of the eye, and its health is vital for maintaining vision. Various diseases, including diabetic retinopathy, retinitis pigmentosa, and age-related macular degeneration, progressively damage the retina and can lead to significant vision impairment. While the physical changes associated with these diseases are well-documented, the chemical signals that influence the retina’s response to injury have been less understood.
Decline of Erucamide in Retinal Degeneration
The researchers discovered that levels of erucamide, which is part of a broader class of fat-like compounds known as lipids, decrease significantly as photoreceptors—cells responsible for detecting light—begin to die. According to Martin Friedlander, a senior author and professor at Scripps Research, this finding suggests that the retina does not merely deteriorate; instead, it actively responds to injury through chemical signaling mechanisms.
Friedlander stated, “Our work identifies erucamide as a signaling molecule that helps coordinate that response,” indicating its potential role in the retina’s defense system.
Investigating Molecular Signals
The research team began their investigation after earlier findings indicated that transplanted stem cell-derived retinal cells could slow degeneration, even after the cells themselves had disappeared. This led to the hypothesis that these cells might be releasing protective chemical signals that had lasting effects. To identify these signals, the researchers employed mass spectrometry-based metabolomics to analyze tissue from established preclinical models of retinal degeneration.
Erucamide emerged as a prominent candidate, as its levels dropped sharply with the onset of photoreceptor deterioration. Co-author Dale Boger, the Richard and Alice Cramer Professor of Chemistry at Scripps Research, noted, “That was a pivotal moment for us. It raised the possibility that erucamide could be influencing how tissue responds and wasn’t just changing as a consequence of disease.” This perspective shifted the focus to how erucamide could be utilized therapeutically.
Delivery and Activation Mechanisms
To test the hypothesis that restoring erucamide could alter the course of retinal degeneration, the scientists developed a method to deliver erucamide into the eye using porous silicon nanoparticles. These engineered carriers allowed for controlled release, crucially addressing the hydrophobic nature of erucamide, which does not dissolve well in water and can clump when injected.
Surprisingly, the results indicated that erucamide did not directly act on the photoreceptors themselves. Instead, it activated CD11b⁺ myeloid cells, a type of immune cell in the retina that responds to injury and contributes to tissue maintenance. Importantly, the researchers identified a protein, TMEM19, that erucamide binds to; reducing TMEM19 levels negated the activation of myeloid cells and eliminated the protective effects of erucamide.
Implications for Future Treatment Strategies
Once activated, these immune cells released signals that supported neurovascular stabilization, promoting the health of nerve cells and the blood vessels supplying them with nutrients. Although erucamide did not reverse retinal degeneration, it slowed certain aspects of the disease by preserving the structure and function of the remaining tissue.
First author Guoqin Wei, a staff scientist at Scripps Research, emphasized the importance of this shift in understanding, stating, “Instead of targeting the photoreceptors themselves, erucamide appears to work by engaging the surrounding environment. That shift in perspective could be important for treating degenerative retinal diseases going forward.” The research team is now exploring the potential of manipulating this signaling pathway further.
Future Research Directions
While the study has provided crucial insights, many questions remain regarding the precise mechanisms through which erucamide operates. Future investigations will focus on how erucamide signaling varies across different retinal diseases and whether adjustments to this pathway can yield long-term benefits.
Moreover, developing erucamide as a viable treatment poses challenges due to its hydrophobic nature, necessitating innovative formulation and delivery methods. The researchers intend to explore modified versions of erucamide, as well as other lipid molecules, to assess their efficacy in activating the retina’s protective responses.
A Broader Perspective on Natural Molecules
The findings from this study support a growing body of evidence suggesting that naturally occurring molecules within the body can be leveraged to enhance tissue resilience to disease. A potential treatment strategy could involve reinforcing existing protective signals that the retina utilizes under stress, rather than introducing entirely new biological processes.
Friedlander concluded, “The goal is to reinforce a signal that’s already present. If we can learn how to modulate that response carefully, it could offer a new path for slowing the progression of retinal diseases where treatment options remain limited.” This research marks a promising step toward developing innovative therapies for retinal degeneration, emphasizing the importance of understanding the retina’s intrinsic defense mechanisms.
The study, titled “A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration,” included contributions from a number of researchers affiliated with Scripps Research, UC San Diego, and the Lowy Medical Research Institute.
This research was supported by multiple funding sources, including the Lowy Medical Research Institute and various grants from the National Institutes of Health and other institutions.
No Comment! Be the first one.